Arxada invests CHF 20M to expand niacin production in Visp

Arxada pledged an investment of CHF 20 million (€20.4 million) to expand production at its Visp, Switzerland facility, focusing on niacin, as part of an extended long-term partnership with Royal DSM.

“This significant new investment in our Visp facility secures the site’s long-term future, helping to fuel our future growth.”nutraingredients.com

• 1 source
• nutraingredients.comArxada and DSM target niacin growth as part of an extended long-term partnershipStephen DaniellsSep 2, 2022

Summarized from public sources; check the original articles before acting on it.